SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Kynurenine 3-monoxygenase (KMO)	Studies in mice suggest small molecule antagonists of KMO could help treat AD. KMO is an enzyme involved in a tryptophan degradation pathway that yields a neurotoxic byproduct. In a mouse model of AD, a non–CNS-penetrant small molecule KMO inhibitor decreased synaptic loss and increased learning and memory compared with vehicle control. Next steps include partnering with a company to complete preclinical development of the KMO inhibitor.	Patent pending; available for licensing	Zwilling, D. *et al. Cell*; published online June 10, 2011; doi:10.1016/j.cell.2011.05.020 **Contact:** Paul J. Muchowski, University of California, San Francisco, Calif. e-mail: pmuchowski@gladstone.ucsf.edu

SciBX 4(26); doi:10.1038/scibx.2011.742
Published online June 30, 2011